AVI says Casey, Henney won't stand for re-election
AVI BioPharma Inc. said Thursday it Michael D. Casey and Christopher S. Henney will not stand for re-election to the company's board of directors for personal reasons.
Their terms end in 2010.
AVI is developing treatments for Duchenne muscular dystrophy and viruses such as Ebola.
Shares fell 6 cents, or 4.1 percent, to $1.28 in premarket trading.